- Home
- SLXN vs MBRX Comparison
SLXN vs MBRX Comparison
Compare SLXN & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLXN
- MBRX
- Stock Information
- Founded
- SLXN 2008
- MBRX 2015
- Country
- SLXN Israel
- MBRX United States
- Employees
- SLXN N/A
- MBRX N/A
- Industry
- SLXN
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- SLXN
- MBRX Health Care
- Exchange
- SLXN NYSE
- MBRX Nasdaq
- Market Cap
- SLXN 4.3M
- MBRX 4.4M
- IPO Year
- SLXN N/A
- MBRX 2016
- Fundamental
- Price
- SLXN $0.85
- MBRX $0.82
- Analyst Decision
- SLXN Strong Buy
- MBRX Strong Buy
- Analyst Count
- SLXN 1
- MBRX 3
- Target Price
- SLXN $5.00
- MBRX $17.33
- AVG Volume (30 Days)
- SLXN 797.9K
- MBRX 640.3K
- Earning Date
- SLXN 05-21-2025
- MBRX 05-09-2025
- Dividend Yield
- SLXN N/A
- MBRX N/A
- EPS Growth
- SLXN N/A
- MBRX N/A
- EPS
- SLXN N/A
- MBRX N/A
- Revenue
- SLXN N/A
- MBRX N/A
- Revenue This Year
- SLXN N/A
- MBRX N/A
- Revenue Next Year
- SLXN N/A
- MBRX N/A
- P/E Ratio
- SLXN N/A
- MBRX N/A
- Revenue Growth
- SLXN N/A
- MBRX N/A
- 52 Week Low
- SLXN $0.21
- MBRX $0.40
- 52 Week High
- SLXN $13.56
- MBRX $5.91
- Technical
- Relative Strength Index (RSI)
- SLXN N/A
- MBRX 34.26
- Support Level
- SLXN N/A
- MBRX $0.92
- Resistance Level
- SLXN N/A
- MBRX $1.04
- Average True Range (ATR)
- SLXN 0.00
- MBRX 0.10
- MACD
- SLXN 0.00
- MBRX -0.02
- Stochastic Oscillator
- SLXN 0.00
- MBRX 9.07
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.